Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
Akeso (OTCMKTS : AKESF ) Stock
MWN-AI** Summary
MWN-AI** Analysis
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Description
Akeso Inc is a clinical-stage biopharmaceutical company committed to in-house discovery, development, and commercialization of therapies. It is dedicated to addressing global unmet medical needs in oncology, immunology, and other therapeutic areas. The company's drug candidates include AK104 for recurrent or metastatic cervical cancer, Penpulimab (AK105) for the treatment of patients with classical Hodgkin's lymphoma, AK112 for advanced solid tumors, AK101 for the treatment of ulcerative colitis, AK111 for moderate-to-severe psoriasis, Ebronucimab (AK102) for the treatment of patients with a high or very high risk of hypercholesterolemia, and others.
Quote
| Last: | $16.70 |
|---|---|
| Change Percent: | -1.76% |
| Open: | $17 |
| Close: | $17 |
| High: | $17 |
| Low: | $15.55 |
| Volume: | 5,037 |
| Last Trade Date Time: | 03/30/2026 12:53:03 pm |
Recent News Releases
Subscribe to Our Newsletter
**MWN-AI FAQ is based on asking OpenAI questions about Akeso (OTCMKTS: AKESF).
